This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
infectious diseases | 3685 |
public health | 3470 |
infectious disease | 2195 |
united states | 2066 |
clinical signs | 2038 |
mg kg | 1480 |
bone marrow | 1300 |
risk factors | 1283 |
acute respiratory | 1168 |
stem cell | 1083 |
may also | 1064 |
respiratory syndrome | 948 |
immune response | 894 |
liver disease | 891 |
climate change | 866 |
immune system | 849 |
lung disease | 827 |
respiratory tract | 812 |
severe acute | 793 |
health care | 788 |
lymph nodes | 709 |
disease control | 689 |
virus infection | 685 |
world health | 682 |
nervous system | 682 |
rheumatoid arthritis | 681 |
mg dl | 677 |
cell transplantation | 670 |
renal failure | 667 |
emerging infectious | 665 |
may occur | 659 |
differential diagnosis | 635 |
gene expression | 625 |
weight loss | 620 |
coronavirus disease | 620 |
clinical trials | 616 |
doc id | 606 |
cord uid | 606 |
health organization | 605 |
peripheral blood | 603 |
pulmonary disease | 572 |
kawasaki disease | 551 |
epithelial cells | 551 |
increased risk | 544 |
sickle cell | 540 |
heart failure | 537 |
important role | 526 |
systematic review | 519 |
heart disease | 517 |
developing countries | 515 |
animal models | 512 |
median age | 511 |
human health | 505 |
lyme disease | 504 |
respiratory disease | 501 |
ebola virus | 490 |
cystic fibrosis | 485 |
novel coronavirus | 485 |
infl uenza | 483 |
one patient | 474 |
disease severity | 471 |
hematopoietic stem | 466 |
risk factor | 465 |
central nervous | 462 |
respiratory distress | 462 |
cardiovascular disease | 462 |
blood pressure | 456 |
high risk | 453 |
side effects | 453 |
viral infections | 452 |
significantly higher | 448 |
avian influenza | 446 |
west nile | 440 |
influenza virus | 436 |
case report | 434 |
chronic obstructive | 434 |
mean age | 434 |
clinical features | 425 |
global health | 420 |
inflammatory response | 419 |
immune responses | 416 |
may cause | 414 |
infectious agents | 414 |
obstructive pulmonary | 410 |
bowel disease | 406 |
stem cells | 405 |
disease outbreaks | 397 |
small intestine | 396 |
gastrointestinal tract | 391 |
renal disease | 390 |
may result | 389 |
physical examination | 387 |
severe disease | 387 |
ng ml | 387 |
lung cancer | 385 |
disease transmission | 383 |
inflammatory bowel | 382 |
human disease | 380 |
years old | 378 |
incubation period | 375 |
kidney disease | 375 |
chain reaction | 373 |
see chapter | 372 |
en el | 369 |
nk cells | 369 |
abdominal pain | 368 |
intensive care | 367 |
disease surveillance | 367 |
patients received | 367 |
diabetes mellitus | 367 |
polymerase chain | 357 |
may lead | 355 |
control measures | 354 |
renal function | 353 |
urinary tract | 353 |
lymph node | 348 |
breast cancer | 347 |
clinical trial | 346 |
north america | 344 |
overall survival | 341 |
clinical practice | 339 |
pediatric patients | 339 |
hemorrhagic fever | 336 |
growth factor | 334 |
pulmonary hypertension | 334 |
endothelial cells | 333 |
flow cytometry | 331 |
statistically significant | 331 |
hiv aids | 329 |
lung function | 329 |
cd cd | 328 |
clinical disease | 325 |
autoimmune diseases | 324 |
zoonotic diseases | 324 |
upper respiratory | 322 |
clinical presentation | 322 |
nile virus | 321 |
critically ill | 321 |
respiratory syncytial | 319 |
pulmonary fibrosis | 318 |
design method | 318 |
viral infection | 314 |
bacterial infections | 314 |
disease activity | 314 |
spinal cord | 313 |
smooth muscle | 312 |
disease risk | 312 |
middle east | 311 |
body weight | 309 |
lupus erythematosus | 309 |
respiratory failure | 307 |
distress syndrome | 307 |
syncytial virus | 306 |
multiple sclerosis | 306 |
animal health | 305 |
cell lines | 305 |
disease progression | 304 |
disease virus | 304 |
commonly used | 302 |
interstitial lung | 300 |
pacientes con | 300 |
syndrome coronavirus | 300 |
cell disease | 300 |
cd cells | 300 |
surveillance systems | 299 |
clinical manifestations | 298 |
type i | 297 |
blood flow | 297 |
borne diseases | 294 |
immunodeficiency virus | 294 |
new york | 293 |
escherichia coli | 291 |
recent years | 290 |
significant difference | 289 |
guinea pigs | 288 |
two patients | 287 |
long term | 287 |
amino acid | 287 |
one health | 286 |
magnetic resonance | 286 |
disease may | 286 |
fatty liver | 286 |
chronic disease | 282 |
respiratory infections | 281 |
mortality rate | 281 |
small intestinal | 280 |
innate immune | 279 |
systemic lupus | 279 |
lung diseases | 276 |
coronary artery | 276 |
nitric oxide | 276 |
blood cells | 276 |
large number | 275 |
interstitial pneumonia | 274 |
kg day | 274 |
retrospective study | 273 |
clinical symptoms | 273 |
chronic diseases | 272 |
cell death | 272 |
mouse model | 271 |
blood cell | 271 |
environmental factors | 270 |
one study | 269 |
virus disease | 269 |
yellow fever | 268 |
clinical course | 267 |
chronic hepatitis | 266 |
significant differences | 264 |
communicable diseases | 263 |
severe cases | 261 |
clinical characteristics | 261 |
host disease | 261 |
adverse events | 260 |
necrosis factor | 260 |
human beings | 259 |
infected individuals | 259 |
cohort study | 258 |
lower respiratory | 256 |
nucleic acid | 253 |
widely used | 253 |
nephrotic syndrome | 252 |
least one | 252 |
disease emergence | 251 |
may develop | 251 |
primary immunodeficiency | 250 |
type diabetes | 250 |
oxidative stress | 249 |
supportive care | 249 |
wide range | 248 |
present study | 248 |
general population | 247 |
computed tomography | 246 |
infected animals | 245 |
red blood | 244 |
per year | 243 |
electron microscopy | 242 |
united kingdom | 241 |
type ii | 240 |
severe covid | 240 |
domestic animals | 239 |
early detection | 238 |
cell lymphoma | 238 |
exome sequencing | 238 |
en pacientes | 238 |
patients treated | 237 |
liver failure | 236 |
will also | 235 |
human immunodeficiency | 234 |
blood samples | 234 |
adverse effects | 233 |
also known | 233 |
diagnostic criteria | 233 |
recent studies | 232 |
pregnant women | 232 |
nipah virus | 231 |
disease prevention | 231 |
control group | 231 |
high levels | 230 |
significantly lower | 230 |
may include | 230 |
causative agent | 230 |
hong kong | 229 |
animal model | 228 |
acute phase | 228 |
definitive diagnosis | 228 |
influenza viruses | 228 |
bacterial infection | 226 |
connective tissue | 226 |
plasma cells | 225 |
zoonotic disease | 223 |
higher risk | 223 |
antibiotic therapy | 223 |
year old | 222 |
se recomienda | 222 |
direct contact | 222 |
controlled trial | 221 |
may help | 221 |
blood vessels | 221 |
west africa | 221 |
inflammatory cytokines | 218 |
tract infections | 218 |
celiac disease | 217 |
million people | 217 |
hiv infection | 217 |
common cause | 216 |
surveillance system | 216 |
heart rate | 215 |
prospective study | 215 |
healthy controls | 215 |
medical care | 214 |
conditioning regimen | 214 |
risk assessment | 214 |
closely related | 213 |
los pacientes | 213 |
two groups | 211 |
acute gvhd | 210 |
monoclonal antibody | 210 |
many cases | 210 |
case reports | 210 |
chronic gvhd | 210 |
mouse models | 210 |
mortality rates | 210 |
among patients | 210 |
hemolytic anemia | 209 |
mechanical ventilation | 208 |
within days | 208 |
tumor necrosis | 208 |
patients without | 208 |
soft tissue | 208 |
immune deficiency | 207 |
staphylococcus aureus | 207 |
autosomal recessive | 206 |
gene therapy | 206 |
viral diseases | 206 |
determine whether | 206 |
lung injury | 206 |
diagnostic tests | 206 |
pulmonary vascular | 205 |
early stages | 204 |
case series | 204 |
dendritic cells | 204 |
natural history | 203 |
median time | 203 |
replacement therapy | 202 |
young children | 202 |
first time | 202 |
may provide | 202 |
median follow | 201 |
social distancing | 200 |
reproduction number | 200 |
patients may | 200 |
cell carcinoma | 199 |
early diagnosis | 199 |
mononuclear cells | 199 |
portal hypertension | 199 |
patients receiving | 199 |
also may | 198 |
years ago | 198 |
adult patients | 198 |
even though | 196 |
family history | 195 |
east respiratory | 195 |
may require | 195 |
myocardial infarction | 194 |
viral load | 194 |
cell count | 194 |
one year | 194 |
three patients | 193 |
surveillance data | 193 |
may contribute | 193 |
naturally occurring | 193 |
introduction background | 193 |
pg ml | 192 |
disease outbreak | 192 |
infection control | 192 |
cell types | 192 |
disease caused | 192 |
skin lesions | 192 |
age group | 191 |
multiple myeloma | 191 |
recent study | 191 |
air travel | 190 |
mouth disease | 190 |
th century | 190 |
learning objectives | 190 |
human genome | 190 |
cell proliferation | 189 |
pandemic influenza | 189 |
immune cells | 189 |
south america | 188 |
primary care | 188 |
per day | 188 |
high mortality | 187 |
infectious agent | 186 |
borna disease | 186 |
disease burden | 186 |
old male | 186 |
con covid | 185 |
see table | 185 |
endemic areas | 184 |
tract infection | 184 |
allogeneic hematopoietic | 184 |
idiopathic pulmonary | 184 |
immune complexes | 183 |
emerging diseases | 183 |
last years | 183 |
affected animals | 183 |
health systems | 182 |
care unit | 181 |
may play | 181 |
large numbers | 181 |
cell surface | 181 |
acute renal | 181 |
results suggest | 180 |
hepatic encephalopathy | 180 |
free survival | 180 |
valley fever | 179 |
mast cell | 179 |
disease spread | 178 |
clinical data | 178 |
saharan africa | 178 |
combined immunodeficiency | 178 |
congenital heart | 177 |
rift valley | 177 |
hospitalized patients | 177 |
left ventricular | 177 |
life cycle | 176 |
biopsy specimens | 176 |
total number | 176 |
colorectal cancer | 176 |
also occur | 176 |
confirmed cases | 176 |
age groups | 175 |
income countries | 175 |
inflammatory diseases | 175 |
antimicrobial resistance | 175 |
small bowel | 175 |
pulmonary function | 175 |
chronic kidney | 175 |
fatality rate | 175 |
significantly associated | 175 |
white blood | 174 |
foreign body | 174 |
transcription factor | 174 |
resonance imaging | 174 |
inflammatory cells | 174 |
health surveillance | 174 |
data collection | 174 |
past years | 173 |
ml min | 173 |
liver biopsy | 173 |
different types | 173 |
amino acids | 173 |
medical records | 173 |
four patients | 172 |
oral health | 171 |
differential diagnoses | 171 |
fatty acids | 171 |
healthy individuals | 171 |
cell culture | 171 |
cytokine storm | 170 |
marrow transplantation | 170 |
old female | 170 |
health services | 170 |
adaptive immune | 170 |
hepatic disease | 170 |
significantly increased | 170 |
respiratory diseases | 169 |
emerging infections | 169 |
developed countries | 169 |
health authorities | 169 |
commercially available | 169 |
autoimmune disease | 169 |
chronic inflammatory | 168 |
young adults | 168 |
family members | 168 |
nk cell | 167 |
health system | 167 |
cerebrospinal fluid | 167 |
newcastle disease | 167 |
case fatality | 167 |
significantly different | 167 |
many patients | 167 |
next generation | 167 |
time series | 166 |
human population | 166 |
infection may | 166 |
veterinary medicine | 166 |
factors associated | 165 |
cell transplant | 165 |
serum creatinine | 165 |
complete remission | 165 |
chronic fatigue | 165 |
chronic inflammation | 165 |
performed using | 164 |
age years | 164 |
pulmonary edema | 164 |
generation sequencing | 164 |
cardiovascular diseases | 164 |
mr imaging | 164 |
disease process | 163 |
older adults | 163 |
ulcerative colitis | 163 |
monoclonal antibodies | 163 |
cell line | 163 |
previous studies | 162 |
syndromic surveillance | 162 |
chest ct | 162 |
zika virus | 161 |
may become | 161 |
lamina propria | 161 |
body mass | 161 |
severe hepatitis | 161 |
air pollution | 161 |
disease dynamics | 161 |
health status | 161 |
underlying disease | 161 |
chronic renal | 160 |
periodontal disease | 160 |
high prevalence | 160 |
previously reported | 159 |
key role | 159 |
molecular mechanisms | 159 |
converting enzyme | 159 |
copd patients | 159 |
bronchoalveolar lavage | 159 |
fever virus | 158 |
less likely | 158 |
fi rst | 158 |
patient care | 157 |
significantly reduced | 157 |
statistical analysis | 157 |
early warning | 157 |
foreign bodies | 156 |
many countries | 156 |
alveolar macrophages | 156 |
whole blood | 156 |
tissue damage | 156 |
one may | 156 |
reported cases | 156 |
several studies | 156 |
ct scan | 155 |
influenza pandemic | 155 |
white matter | 155 |
genetic testing | 155 |
cell counts | 154 |
bile acids | 154 |
liver function | 154 |
mg ml | 154 |
ill patients | 153 |
national institute | 153 |
gvhd prophylaxis | 153 |
infl ammation | 153 |
dengue virus | 153 |
drinking water | 153 |
mucous membranes | 153 |
mycobacterium tuberculosis | 152 |
fungal infections | 152 |
also found | 152 |
cord blood | 151 |
data suggest | 151 |
one case | 151 |
innate immunity | 151 |
close contact | 150 |
vaccine development | 150 |
case study | 150 |
patients undergoing | 150 |
clinical diagnosis | 149 |
rabies virus | 148 |
septic shock | 148 |
disease patients | 148 |
global burden | 148 |
decision making | 148 |
states background | 148 |
health problems | 147 |
two cases | 147 |
liver enzymes | 147 |
less common | 147 |
herpes simplex | 147 |
reactive protein | 146 |
whole exome | 146 |
portal vein | 146 |
fatigue syndrome | 146 |
inflammatory disease | 146 |
laboratory animal | 146 |
insulin resistance | 146 |
well tolerated | 146 |
natural killer | 146 |
better understanding | 145 |
otitis media | 145 |
nonalcoholic fatty | 145 |
acute lymphoblastic | 145 |
literature review | 145 |
inflammatory mediators | 144 |
small animal | 144 |
laboratory findings | 144 |
tumor cells | 144 |
pet ct | 144 |
another study | 144 |
gastrointestinal disease | 144 |
united nations | 144 |
infl ammatory | 144 |
highly pathogenic | 143 |
normal range | 143 |
higher levels | 143 |
contact tracing | 143 |
major cause | 143 |
human populations | 143 |
critical care | 142 |
clinical outcomes | 142 |
leading cause | 142 |
autosomal dominant | 142 |
imaging techniques | 141 |
human diseases | 141 |
wide variety | 141 |
will require | 141 |
renal biopsy | 141 |
time pcr | 141 |
intravascular coagulation | 141 |
disseminated intravascular | 141 |
immune dysregulation | 141 |
animal diseases | 141 |
secondary bacterial | 141 |
international health | 141 |
class i | 141 |
mast cells | 140 |
two different | 140 |
poor prognosis | 140 |
data analysis | 140 |
airway obstruction | 140 |
viral replication | 140 |
small cell | 140 |
myeloid leukemia | 140 |
pleural effusion | 139 |
signs include | 139 |
dengue fever | 139 |
en los | 139 |
will help | 139 |
mg day | 139 |
sexually transmitted | 139 |
virus infections | 139 |
class ii | 139 |
human transmission | 139 |
gi tract | 138 |
antibiotic resistance | 138 |
transmission dynamics | 138 |
systemic inflammation | 138 |
lymphoblastic leukemia | 138 |
barr virus | 138 |
guinea pig | 138 |
host species | 138 |
rna viruses | 138 |
may increase | 137 |
respiratory symptoms | 137 |
research complications | 137 |
fi ndings | 137 |
high dose | 137 |
informed consent | 136 |
imaging findings | 136 |
european countries | 136 |
recurrent infections | 136 |
also cause | 136 |
health problem | 136 |
protein expression | 136 |
see also | 135 |
randomized controlled | 135 |
bile duct | 135 |
new cases | 135 |
may present | 134 |
transplant recipients | 134 |
high level | 134 |
basement membrane | 134 |
chronic liver | 134 |
gold standard | 134 |
canine distemper | 134 |
effective treatment | 134 |
clinical studies | 133 |
large intestine | 133 |
basic reproduction | 133 |
clinical findings | 133 |
squamous cell | 133 |
small number | 132 |
cancer patients | 132 |
report text | 132 |
rheumatic diseases | 132 |
abstract case | 132 |
gut microbiota | 132 |
cause disease | 132 |
giant cell | 131 |
antibiotic treatment | 131 |
within hours | 131 |
ml kg | 131 |
mathematical models | 131 |
european union | 131 |
university hospital | 131 |
human infection | 131 |
ebola outbreak | 131 |
year period | 131 |
old boy | 131 |
working group | 130 |
oral cavity | 130 |
acute myeloid | 130 |
physical activity | 130 |
wild animals | 130 |
infected patients | 130 |
patients developed | 130 |
treatment options | 130 |
clostridium difficile | 130 |
related diseases | 130 |
animals may | 130 |
complete blood | 130 |
congestive heart | 130 |
platelet count | 129 |
antibody response | 129 |
healthy dogs | 129 |
five patients | 129 |
organ failure | 129 |
laboratory tests | 129 |
stage renal | 129 |
laboratory animals | 129 |
cell activation | 128 |
inflammatory responses | 128 |
significant increase | 128 |
medical center | 128 |
many years | 128 |
intestinal mucosa | 128 |
disease ecology | 128 |
sir model | 128 |
phase i | 128 |
graft failure | 127 |
uric acid | 127 |
viral disease | 127 |
drug resistance | 127 |
become infected | 127 |
medical history | 127 |
haemophilus influenzae | 127 |
reactive oxygen | 127 |
respiratory infection | 127 |
airway inflammation | 127 |
retrospective diagnosis | 127 |
machine learning | 127 |
every hours | 126 |
national health | 126 |
elderly patients | 126 |
identifi ed | 126 |
first year | 126 |
will continue | 126 |
human cases | 126 |
blood transfusion | 125 |
host immune | 125 |
disease management | 125 |
cell tumors | 125 |
evidence suggests | 125 |
drug administration | 125 |
metabolic syndrome | 125 |
high incidence | 124 |
low levels | 124 |
logistic regression | 124 |
weight gain | 124 |
real time | 124 |
food safety | 123 |
well known | 123 |
may affect | 123 |
old girl | 123 |
respiratory viruses | 122 |
lung tissue | 122 |
el uso | 122 |
developing world | 122 |
early stage | 122 |
tropical diseases | 122 |
cardiovascular risk | 122 |
borne disease | 122 |
body fluids | 121 |
among children | 121 |
health promotion | 121 |
plasma membrane | 121 |
often associated | 121 |
artery disease | 121 |
chart review | 121 |
clostridium perfringens | 121 |
blood count | 121 |
protein kinase | 121 |
two decades | 120 |
serum samples | 120 |
imaging modalities | 120 |
cell receptor | 120 |
pilot study | 120 |
granulomatous disease | 120 |
findings suggest | 120 |
systemic disease | 120 |
southeast asia | 120 |
global public | 119 |
sars coronavirus | 119 |
previously described | 119 |
serum levels | 119 |
neurodegenerative diseases | 119 |
predictive value | 119 |
patients showed | 118 |
antibody titers | 118 |
signaling pathways | 118 |
six patients | 118 |
red cell | 118 |
control study | 118 |
large amounts | 117 |
national institutes | 117 |
health policy | 117 |
wide association | 117 |
first case | 117 |
hepatic lipidosis | 117 |
viral rna | 117 |
test results | 117 |
allogeneic hsct | 117 |
liver diseases | 117 |
peritoneal fluid | 116 |
communicable disease | 116 |
inclusion criteria | 116 |
liver injury | 116 |
years later | 116 |
pulmonary artery | 116 |
chest pain | 116 |
health professionals | 116 |
studies suggest | 116 |
st century | 116 |
common clinical | 116 |
chronic lung | 116 |
study showed | 115 |
function tests | 115 |
vector control | 115 |
molecular biology | 115 |
study group | 115 |
severe combined | 115 |
increased susceptibility | 114 |
lesions may | 114 |
hepatocellular carcinoma | 114 |
tyrosine kinase | 114 |
blood glucose | 114 |
liver transplantation | 114 |
bacterial pneumonia | 114 |
dna methylation | 114 |
newborn screening | 113 |
multivariate analysis | 113 |
intravenous immunoglobulin | 113 |
cmv reactivation | 113 |
grade iii | 113 |
del paciente | 113 |
task force | 113 |
cd ra | 113 |
diffuse alveolar | 113 |
clinical management | 113 |
signaling pathway | 113 |
graft versus | 113 |
cigarette smoke | 112 |
preventive measures | 112 |
time period | 112 |
statistical significance | 112 |
mental health | 112 |
often used | 112 |
pulmonary embolism | 112 |
signifi cant | 112 |
immune reconstitution | 112 |
also important | 111 |
term follow | 111 |
atopic dermatitis | 111 |
genome sequencing | 111 |
molecular weight | 111 |
metabolic acidosis | 111 |
deficient mice | 111 |
cytokine production | 111 |
animal species | 111 |
alkaline phosphatase | 110 |
shock syndrome | 110 |
many different | 110 |
glomerular filtration | 110 |
endoplasmic reticulum | 110 |
host range | 110 |
will provide | 110 |
cancer cells | 109 |
disease course | 109 |
may reveal | 109 |
immunosuppressive therapy | 109 |
western blot | 109 |
retrospective analysis | 109 |
underlying cause | 109 |
recent advances | 109 |
emerging disease | 109 |
frontotemporal dementia | 109 |
mrna expression | 109 |
disease will | 109 |
risk management | 109 |
allogeneic stem | 109 |
cmv infection | 108 |
mass spectrometry | 108 |
higher incidence | 108 |
medical treatment | 108 |
drug discovery | 108 |
life expectancy | 108 |
human infectious | 108 |
unrelated donor | 108 |
several days | 107 |
acute chest | 107 |
proinflammatory cytokines | 107 |
time points | 107 |
intestinal tract | 107 |
hematopoietic cell | 107 |
emergency department | 107 |
oxygen species | 107 |
may appear | 107 |
currently available | 107 |
versus host | 107 |
health emergency | 107 |
endothelial cell | 107 |
increased levels | 106 |
also present | 106 |
environmental conditions | 106 |
fluid therapy | 106 |
newly diagnosed | 106 |
virus type | 106 |
care workers | 106 |
related mortality | 106 |
alveolar damage | 106 |
biomedical research | 106 |
land use | 106 |
major role | 106 |
may represent | 106 |
cell anaemia | 106 |
vascular disease | 106 |
human pathogens | 106 |
significantly decreased | 106 |
balkan nephropathy | 106 |
cumulative incidence | 105 |
mycophenolate mofetil | 105 |
emerging pathogens | 105 |
common causes | 105 |
diseases caused | 105 |
cardiac disease | 105 |
clinical picture | 105 |
several years | 105 |
first step | 105 |
epithelial cell | 105 |
diagnostic accuracy | 104 |
negative bacteria | 104 |
social media | 104 |
animal disease | 104 |
infected cells | 104 |
myeloid cells | 104 |
clinical outcome | 104 |
north american | 103 |
patients infected | 103 |
skeletal muscle | 103 |
control strategies | 103 |
body condition | 103 |
giant cells | 103 |
chronic granulomatous | 103 |
vascular endothelial | 103 |
transgenic mice | 103 |
streptococcus pneumoniae | 103 |
clinically significant | 103 |
health outcomes | 103 |
immunosorbent assay | 102 |
severely affected | 102 |
influenza vaccine | 102 |
early childhood | 102 |
laboratory mice | 102 |
immune function | 102 |
results indicate | 102 |
interstitial fibrosis | 102 |
critical role | 102 |
cell function | 102 |
global warming | 102 |
pulmonary arterial | 102 |
respiratory system | 102 |
health insurance | 102 |
may show | 102 |
acute liver | 101 |
sierra leone | 101 |
encephalitis virus | 101 |
south africa | 101 |
authors declare | 101 |
adipose tissue | 101 |
common variable | 101 |
pseudomonas aeruginosa | 101 |
antimicrobial therapy | 101 |
first described | 101 |
specific antibodies | 101 |
fungal infection | 100 |
disease models | 100 |
disease incidence | 100 |
commonly seen | 100 |
sudden death | 100 |
health threats | 100 |
observational study | 100 |
immunocompromised patients | 100 |
rhesus macaques | 99 |
based surveillance | 99 |
population size | 99 |
companion animals | 99 |
among others | 99 |
opportunistic infections | 99 |
lassa fever | 99 |
renal tubular | 99 |
like receptors | 99 |
analysis revealed | 99 |
coronavirus infection | 99 |
additional file | 99 |
analysis showed | 99 |
chest syndrome | 98 |
spotted fever | 98 |
systems biology | 98 |
cell membrane | 98 |
copy number | 98 |
two years | 98 |
one hundred | 98 |
donor chimerism | 98 |
para el | 98 |
genetic variants | 98 |
epidemiological studies | 98 |
american college | 98 |
body temperature | 98 |
near future | 98 |
chronic respiratory | 98 |
endemic nephropathy | 98 |
phase ii | 98 |
fecal samples | 98 |
brain injury | 98 |
low dose | 98 |
high doses | 98 |
gross lesions | 98 |
patients died | 98 |
vast majority | 97 |
equine encephalitis | 97 |
clinical history | 97 |
twice daily | 97 |
spongiform encephalopathy | 97 |
parasitic diseases | 97 |
sars outbreak | 97 |
cell cycle | 97 |
diagnostic tool | 97 |
helicobacter pylori | 97 |
urinary bladder | 97 |
borrelia burgdorferi | 97 |
phase iii | 97 |
one must | 97 |
increased serum | 97 |
crucial role | 97 |
cells may | 97 |
sample size | 97 |
cases per | 97 |
patient developed | 97 |
study period | 97 |
patients presenting | 96 |
nine patients | 96 |
acute lung | 96 |
hodgkin lymphoma | 96 |
con el | 96 |
immune complex | 96 |
may reflect | 96 |
el paciente | 96 |
systemic inflammatory | 96 |
kg po | 96 |
lymphoid tissue | 96 |
susceptible individuals | 96 |
situ hybridization | 96 |
seasonal influenza | 96 |
also used | 96 |
tract disease | 96 |
signs may | 95 |
imaging modality | 95 |
wild birds | 95 |
will discuss | 95 |
juvenile idiopathic | 95 |
radiation therapy | 95 |
biliary tract | 95 |
blood loss | 95 |
renal transplantation | 95 |
hendra virus | 95 |
six months | 95 |
small molecule | 95 |
inflammatory markers | 95 |
protective equipment | 94 |
cvid patients | 94 |
renal insufficiency | 94 |
surgical resection | 94 |
human body | 94 |
big data | 94 |
immunodeficiency syndrome | 94 |
rheumatic disease | 94 |
extracellular matrix | 94 |
common cold | 94 |
survival rate | 94 |
por covid | 94 |
health risks | 94 |
vena cava | 93 |
seven patients | 93 |
one hand | 93 |
mhc class | 93 |
antiviral drugs | 93 |
arterial blood | 93 |
optimal control | 93 |
healthy children | 93 |
children aged | 93 |
diagnostic test | 93 |
virus vaccine | 93 |
like receptor | 93 |
bile ducts | 93 |
health interventions | 93 |
etiologic agent | 93 |
japanese encephalitis | 93 |
poorly understood | 93 |
linked immunosorbent | 93 |
york city | 93 |
idiopathic arthritis | 93 |
health issues | 92 |
simplex virus | 92 |
feline infectious | 92 |
three times | 92 |
primary immunodeficiencies | 92 |
bovine tuberculosis | 92 |
growth factors | 92 |
transmission occurs | 92 |
fi brosis | 92 |
data sources | 92 |
will increase | 92 |
latin america | 92 |
world war | 92 |
personal protective | 92 |
ex vivo | 92 |
quality control | 92 |
industrialized countries | 92 |
disease associated | 91 |
two weeks | 91 |
become familiar | 91 |
increased expression | 91 |
genetic factors | 91 |
histologic study | 91 |
successfully treated | 91 |
respiratory illness | 91 |
beneficial effects | 91 |
cell subsets | 91 |
future studies | 91 |
mild disease | 91 |
retrospective chart | 91 |
airway disease | 91 |
potential role | 91 |
significant reduction | 91 |
healthcare workers | 91 |
cause severe | 91 |
compound heterozygous | 91 |
severe respiratory | 91 |
whole body | 90 |
twentieth century | 90 |
successful treatment | 90 |
many studies | 90 |
alcoholic fatty | 90 |
combination therapy | 90 |
lopinavir ritonavir | 90 |
better understand | 90 |
clinical improvement | 90 |
wound healing | 90 |
specific antibody | 90 |
days later | 90 |
disease status | 90 |
new insights | 90 |
virus isolation | 90 |
index case | 90 |
study found | 90 |
chronic bronchitis | 90 |
hospital admission | 90 |
severe asthma | 90 |
health regulations | 90 |
least two | 90 |
antibody responses | 90 |
last decade | 89 |
imaging studies | 89 |
patients diagnosed | 89 |
often present | 89 |
mycobacterium avium | 89 |
three groups | 89 |
pathologic findings | 89 |
clinically relevant | 89 |
new disease | 89 |
association studies | 89 |
transmitted diseases | 89 |
several weeks | 89 |
receptor antagonist | 89 |
takes place | 89 |
viral hepatitis | 89 |
findings include | 89 |
five years | 89 |
adaptive immunity | 89 |
nasal discharge | 88 |
measles virus | 88 |
food production | 88 |
infected individual | 88 |
may reduce | 88 |
zoonotic pathogens | 88 |
central role | 88 |
readily available | 88 |
mm hg | 88 |
affected individuals | 88 |
fatty acid | 88 |
may need | 88 |
clinical research | 88 |
signal transduction | 88 |
blood stem | 88 |
population dynamics | 88 |
ambient temperature | 88 |
patients aged | 88 |
randomized clinical | 88 |
filtration rate | 88 |
health workers | 88 |
hearing loss | 88 |
th cells | 88 |
trem variants | 87 |
may involve | 87 |
acute infection | 87 |
cell lung | 87 |
cognitive impairment | 87 |
muscle cells | 87 |
will lead | 87 |
inclusion bodies | 87 |
gastric ulcers | 87 |
persistent infection | 87 |
much less | 87 |
population health | 87 |
acquired immunodeficiency | 87 |
two major | 87 |
current study | 87 |
well established | 87 |
high degree | 87 |
associated conditions | 87 |
highly contagious | 87 |
large colon | 87 |
infectious peritonitis | 87 |
synovial fluid | 87 |
therapeutic strategies | 87 |
surgical treatment | 87 |
experimental infection | 87 |
distemper virus | 87 |
pediatric population | 87 |
birth weight | 87 |
immune cell | 87 |
treatment strategies | 86 |
mesenteric lymph | 86 |
genetic analysis | 86 |
sequence analysis | 86 |
brain tissue | 86 |
will develop | 86 |
aged years | 86 |
presentation will | 86 |
retrospective cohort | 86 |
matched unrelated | 86 |
several months | 86 |
nucleic acids | 86 |
variable immunodeficiency | 86 |
protective effect | 86 |
brain barrier | 86 |
care providers | 86 |
vaccination programs | 86 |
interest reported | 86 |
saudi arabia | 86 |
urban areas | 86 |
commonly associated | 86 |
transforming growth | 86 |
disease onset | 86 |
herd immunity | 86 |
positive results | 85 |
confidence interval | 85 |
genetic diversity | 85 |
must also | 85 |
binding protein | 85 |
cell cultures | 85 |
natural selection | 85 |
red pulp | 85 |
west african | 85 |
patients underwent | 85 |
iron deficiency | 85 |
first reported | 85 |
results show | 85 |
genome sequence | 85 |
active disease | 85 |
renal involvement | 85 |
lung biopsy | 85 |
patients presented | 85 |
toxoplasma gondii | 85 |
cytokine release | 85 |
incidence rate | 85 |
hepatic necrosis | 85 |
less frequently | 85 |
blood gas | 84 |
adhesion molecules | 84 |
dental care | 84 |
pathological changes | 84 |
animal medicine | 84 |
wild type | 84 |
months later | 84 |
trem expression | 84 |
case studies | 84 |
patient population | 84 |
mitral valve | 84 |
diagnostic imaging | 84 |
bile acid | 84 |
disease susceptibility | 84 |
ad patients | 84 |
specific disease | 84 |
frequently used | 84 |
retrospective review | 84 |
steroid therapy | 84 |
disease processes | 84 |
less severe | 84 |
clinical information | 84 |
also reported | 84 |
new technologies | 84 |
will need | 84 |
myeloablative conditioning | 84 |
specific treatment | 84 |
toxic shock | 84 |
regression analysis | 84 |
haemorrhagic fever | 83 |
progressive disease | 83 |
cardiac rehabilitation | 83 |
two types | 83 |
months post | 83 |
health information | 83 |
elevated serum | 83 |
take place | 83 |
differential equations | 83 |
hepatobiliary disease | 83 |
right ventricular | 83 |
clinical use | 83 |
possible associated | 83 |
tissue culture | 83 |
vascular resistance | 83 |
respiratory pathogens | 83 |
rocky mountain | 83 |
molecular basis | 83 |
host cells | 83 |
many diseases | 83 |
international travel | 83 |
oral administration | 83 |
survival time | 83 |
affected dogs | 83 |
consecutive patients | 82 |
data collected | 82 |
i will | 82 |
grade ii | 82 |
pulmonary syndrome | 82 |
gene transfer | 82 |
different stages | 82 |
clinical significance | 82 |
risk groups | 82 |
disease characterized | 82 |
patients will | 82 |
times higher | 82 |
epidemiological data | 82 |
aedes aegypti | 82 |
human infections | 82 |
rural areas | 82 |
peritoneal cavity | 82 |
eight patients | 82 |
much higher | 82 |
one month | 82 |
health security | 81 |
positive patients | 81 |
systemic sclerosis | 81 |
rare disease | 81 |
also observed | 81 |
human microbiome | 81 |
will become | 81 |
global spread | 81 |
clinical examination | 81 |
cd cell | 81 |
studies showed | 81 |
primary immune | 81 |
myocardial injury | 81 |
perfringens type | 81 |
first months | 81 |
adverse reactions | 81 |
nutritional status | 81 |
factor receptor | 81 |
within months | 81 |
therapy may | 81 |
inflammatory process | 81 |
also play | 81 |
potential therapeutic | 81 |
prospective studies | 81 |
immune status | 81 |
first report | 81 |
common diseases | 81 |
pathogen transmission | 81 |
alzheimer disease | 81 |
intestinal obstruction | 81 |
severe infections | 81 |
days post | 81 |
host cell | 81 |
important factor | 80 |
cruise ships | 80 |
mechanisms underlying | 80 |
fl ow | 80 |
high rate | 80 |
bacterial pathogens | 80 |
increased incidence | 80 |
long time | 80 |
will allow | 80 |
pulmonary alveolar | 80 |
may explain | 80 |
long periods | 80 |
blood cultures | 80 |
future research | 80 |
vertical transmission | 80 |
respiratory viral | 80 |
microscopic examination | 80 |
antibiotic use | 80 |
information systems | 80 |
general anesthesia | 80 |
bronchiolitis obliterans | 80 |
controlled trials | 80 |
average number | 80 |
meningococcal disease | 79 |
several factors | 79 |
antibody deficiency | 79 |
risk mitigation | 79 |
healthy subjects | 79 |
disease occurs | 79 |
corticosteroid therapy | 79 |
th percentile | 79 |
mediated immunity | 79 |
transmission rate | 79 |
data indicate | 79 |
necropsy findings | 79 |
million deaths | 79 |
passive transfer | 79 |
cell lymphopenia | 79 |
nasal cavity | 79 |
experimentally infected | 79 |
high frequency | 79 |
ovarian cancer | 79 |
chronic infection | 79 |
transplant patients | 79 |
also associated | 79 |
host defense | 79 |
higher prevalence | 79 |
varying degrees | 79 |
cases reported | 79 |
marrow transplant | 79 |
major histocompatibility | 79 |
cases may | 79 |
fl uid | 79 |
may indicate | 79 |
enzyme activity | 79 |
immunoglobulin replacement | 79 |
cell therapy | 79 |
cells ul | 79 |
immunodeficient mice | 79 |
pulmonary rehabilitation | 79 |
missense mutation | 79 |
broad spectrum | 78 |
infected mice | 78 |
hantavirus pulmonary | 78 |
pd patients | 78 |
defense mechanisms | 78 |
francisella tularensis | 78 |
carbon monoxide | 78 |
population density | 78 |
inflammatory conditions | 78 |
information regarding | 78 |
new zealand | 78 |
lesser extent | 78 |
plasmodium falciparum | 78 |
early phase | 78 |
patients hospitalized | 78 |
nonalcoholic steatohepatitis | 78 |
disease epidemiology | 78 |
disease pathogenesis | 78 |
neglected tropical | 78 |
new infections | 78 |
coronary heart | 78 |
patients admitted | 78 |
high sensitivity | 78 |
drug development | 78 |
large scale | 78 |
first days | 78 |
diagnostic methods | 78 |
therapeutic target | 78 |
identifi cation | 78 |
acute hepatitis | 77 |
economic impact | 77 |
iron overload | 77 |
active surveillance | 77 |
diseases may | 77 |
sore throat | 77 |
aspiration pneumonia | 77 |
prognostic factors | 77 |
fatal disease | 77 |
whole genome | 77 |
greater risk | 77 |
diagnostic tools | 77 |
cell type | 77 |
deep learning | 77 |
diseases including | 77 |
gestational age | 77 |
elevated levels | 77 |
analyzed using | 77 |
like illness | 77 |
promising results | 77 |
protein levels | 77 |
serum albumin | 77 |
umbilical cord | 77 |
single center | 77 |
taken together | 77 |
autologous stem | 77 |
healthy donors | 77 |
portosystemic shunting | 77 |
electronic health | 77 |
biological agents | 77 |
genes involved | 77 |
high resolution | 77 |
positive correlation | 77 |
blood mononuclear | 77 |
regional lymph | 77 |
prostate cancer | 77 |
genetic variation | 76 |
asthmatic patients | 76 |
chronic diarrhea | 76 |
diagnostic value | 76 |
health officials | 76 |
pasteurella multocida | 76 |
hepatic copper | 76 |
clinical cases | 76 |
laboratory data | 76 |
mass index | 76 |
observational studies | 76 |
infectious complications | 76 |
chagas disease | 76 |
within weeks | 76 |
cardiac output | 76 |
neurological disease | 76 |
measured using | 76 |
radiation dose | 76 |
health risk | 76 |
vivi disease | 76 |
treatment option | 76 |
first line | 76 |
acquired pneumonia | 76 |
intellectual disability | 76 |
arterial hypertension | 76 |
term survival | 76 |
cervical cancer | 76 |
bovine spongiform | 76 |
large bowel | 76 |
pleural effusions | 76 |
virus transmission | 76 |
high fever | 76 |
lymphocyte subsets | 76 |
virus replication | 76 |
therapeutic targets | 76 |
treatment may | 76 |
significant correlation | 76 |
con sospecha | 76 |
million cases | 76 |
presenting cells | 76 |
increasing number | 76 |
adult horses | 76 |
three cases | 76 |
rights reserved | 75 |
parkinson disease | 75 |
randomized trial | 75 |
acute pancreatitis | 75 |
precision medicine | 75 |
disease threats | 75 |
month period | 75 |
past decade | 75 |
diagnostic testing | 75 |
health approach | 75 |
high morbidity | 75 |
prairie dogs | 75 |
jakob disease | 75 |
healthy control | 75 |
health measures | 75 |
therapeutic options | 75 |
association study | 75 |
portosystemic shunts | 75 |
common finding | 75 |
severity score | 75 |
may serve | 75 |
acute myocardial | 75 |
lymphocyte count | 75 |
relative risk | 75 |
nonhuman primates | 75 |
two main | 75 |
neonatal foals | 75 |
available data | 75 |
differentially expressed | 75 |
positive cells | 75 |
may vary | 75 |
every year | 75 |
conditioning regimens | 75 |
relatively high | 75 |
acute leukemia | 74 |
inflammatory drugs | 74 |
biopsy samples | 74 |
secondary infections | 74 |
important cause | 74 |
infections may | 74 |
older age | 74 |
sle patients | 74 |
kg body | 74 |
potential risk | 74 |
also showed | 74 |
blood transfusions | 74 |
hepatic failure | 74 |
respiratory rate | 74 |
liver fibrosis | 74 |
light microscopy | 74 |
disease due | 74 |
viral hemorrhagic | 74 |
gut microbiome | 74 |
highly sensitive | 74 |
made available | 74 |
will focus | 74 |
cruise ship | 74 |
infectious individuals | 74 |
reproductive number | 74 |
may take | 74 |
clinical relevance | 74 |
based approach | 74 |
complement activation | 74 |
natural kind | 74 |
plasma cell | 74 |
chronic conditions | 73 |
experimental models | 73 |
cell anemia | 73 |
member states | 73 |
inflammatory reaction | 73 |
per patient | 73 |
sars epidemic | 73 |
sin embargo | 73 |
infections caused | 73 |
significant decrease | 73 |
short term | 73 |
average age | 73 |
macrophage activation | 73 |
environmental health | 73 |
water supply | 73 |
relatively low | 73 |
median number | 73 |
colon cancer | 73 |
coronary arteries | 73 |
gas exchange | 73 |
intermediate host | 73 |
democratic republic | 73 |
cov infection | 73 |
infected people | 73 |
host population | 73 |
specimen preparation | 73 |
three different | 73 |
contaminated food | 73 |
also seen | 73 |
clinical evidence | 72 |
high concentrations | 72 |
epidemic models | 72 |
treatment response | 72 |
medical conditions | 72 |
expected findings | 72 |
neurologic signs | 72 |
additional information | 72 |
influenza vaccination | 72 |
sectional study | 72 |
viral shedding | 72 |
nineteenth century | 72 |
remains unknown | 72 |
case definitions | 72 |
well documented | 72 |
particularly important | 72 |
genomic dna | 72 |
surface area | 72 |
usually present | 72 |
bovine viral | 72 |
metabolic disorders | 72 |
studies using | 72 |
might also | 72 |
developmental delay | 72 |
multiple organ | 72 |
paciente con | 72 |
economic development | 72 |
limited number | 72 |
adrenal gland | 72 |
scoring system | 72 |
policy makers | 72 |
host response | 72 |
evolutionary biology | 72 |
population growth | 72 |
antiretroviral therapy | 72 |
histocompatibility complex | 72 |
survival rates | 72 |
persistently infected | 72 |
black death | 72 |
several different | 72 |
leukemia virus | 72 |
uremic syndrome | 72 |
months old | 72 |
yersinia pestis | 72 |
one third | 71 |
social networks | 71 |
clinical phenotype | 71 |
early onset | 71 |
intestinal disease | 71 |
significant risk | 71 |
serum biochemical | 71 |
rare diseases | 71 |
atrial fibrillation | 71 |
naturally infected | 71 |
remains unclear | 71 |
dilated cardiomyopathy | 71 |
clinical response | 71 |
lesions include | 71 |
diarrheal diseases | 71 |
health infrastructure | 71 |
needle aspiration | 71 |
red cells | 71 |
antiviral therapy | 71 |
affected patients | 71 |
pediatric oncology | 71 |
initial treatment | 71 |
ankylosing spondylitis | 71 |
stimulating factor | 71 |
chikungunya virus | 71 |
experimental studies | 71 |
renal dysfunction | 71 |
univariate analysis | 71 |
single dose | 71 |
vibrio cholerae | 71 |
pathogenic avian | 70 |
sanger sequencing | 70 |
young animals | 70 |
mountain spotted | 70 |
diseases like | 70 |
year os | 70 |
preliminary results | 70 |
low risk | 70 |
human medicine | 70 |
sleep apnea | 70 |
disease diagnosis | 70 |
accurate diagnosis | 70 |
different countries | 70 |
renal transplant | 70 |
nutritional support | 70 |
will review | 70 |
acute kidney | 70 |
marrow failure | 70 |
murine model | 70 |
fold increase | 70 |
serum ferritin | 70 |
local health | 70 |
may contain | 70 |
life span | 70 |
secondary prevention | 70 |
standard deviation | 70 |
kidney injury | 70 |
cardiovascular system | 70 |
although many | 70 |
case presentation | 70 |
liver cirrhosis | 70 |
hemorrhagic fevers | 70 |
mycobacterium bovis | 70 |
acute onset | 70 |
also affect | 70 |
reference range | 69 |
odds ratio | 69 |
clinical evaluation | 69 |
different diseases | 69 |
health education | 69 |
disease model | 69 |
medical research | 69 |
regression model | 69 |
blood supply | 69 |
extremely rare | 69 |
virulence factors | 69 |
cynomolgus macaques | 69 |
dental schools | 69 |
will likely | 69 |
drug therapy | 69 |
medical management | 69 |
urine samples | 69 |
natural infection | 69 |
well understood | 69 |
neoplastic cells | 69 |
ischemic heart | 69 |
lung parenchyma | 69 |
rna virus | 69 |
blood volume | 69 |
human behavior | 69 |
age range | 69 |
abdominal ultrasound | 69 |
transcription factors | 69 |
statistical methods | 69 |
provide information | 69 |
african countries | 69 |
treated patients | 69 |
renal syndrome | 69 |
balkan endemic | 69 |
rat model | 69 |
myasthenia gravis | 69 |
world bank | 69 |
unrelated donors | 69 |
cell differentiation | 69 |
kawasaki syndrome | 69 |
primary pulmonary | 69 |
dental disease | 69 |
patient management | 69 |
preventive behavior | 68 |
individual patient | 68 |
serum bile | 68 |
reduced intensity | 68 |
primary disease | 68 |
significant impact | 68 |
one week | 68 |
older people | 68 |
folic acid | 68 |
least months | 68 |
matched sibling | 68 |
pattern recognition | 68 |
health research | 68 |
small ruminants | 68 |
middle ear | 68 |
acute disease | 68 |
also possible | 68 |
single nucleotide | 68 |
viral diarrhea | 68 |
results showed | 68 |
platelet aggregation | 68 |
economic losses | 68 |
also called | 67 |
incidence rates | 67 |
candidate genes | 67 |
abdominal cavity | 67 |
give rise | 67 |
liver enzyme | 67 |
risks associated | 67 |
antimicrobial agents | 67 |
case definition | 67 |
kupffer cells | 67 |
lactate dehydrogenase | 67 |
aplastic anemia | 67 |
intensity conditioning | 67 |
internal medicine | 67 |
like disease | 67 |
human genetics | 67 |
surgical intervention | 67 |
dependent manner | 67 |
much lower | 67 |
ct findings | 67 |
kidney failure | 67 |
usually occurs | 67 |
whenever possible | 67 |
fatality rates | 67 |
gene encoding | 67 |
organ systems | 67 |
health departments | 67 |
expression levels | 67 |
knockout mice | 67 |
related terms | 67 |
within normal | 67 |
wide spectrum | 67 |
type iii | 67 |
examination findings | 67 |
infection risk | 67 |
less commonly | 67 |
limited data | 67 |
protective immunity | 67 |
another important | 67 |
medical therapy | 66 |
laboratory testing | 66 |
drug reactions | 66 |
health service | 66 |
liver damage | 66 |
cell source | 66 |
treatment modalities | 66 |
neutrophil engraftment | 66 |
per cent | 66 |
three major | 66 |
pivotal role | 66 |
reverse transcriptase | 66 |
target cells | 66 |
psychological stress | 66 |
appropriate treatment | 66 |
fruit bats | 66 |
cd count | 66 |
palliative care | 66 |
antiviral activity | 66 |
endothelial dysfunction | 66 |
intermediate hosts | 66 |
lower levels | 66 |
significant improvement | 66 |
east asia | 66 |
lysosomal storage | 66 |
will depend | 66 |
con un | 66 |
defi ciency | 66 |
patient presented | 66 |
salivary glands | 66 |
swine fever | 66 |
normal values | 66 |
intestinal epithelial | 66 |
lung transplantation | 66 |
ct scans | 66 |
billion people | 66 |
factors including | 66 |
pcr assay | 66 |
health agencies | 66 |
medical imaging | 66 |
mass gatherings | 66 |
highly variable | 66 |
airway epithelial | 66 |
significant association | 66 |
solid tumors | 66 |
epidemiological transition | 66 |
rabies vaccine | 66 |
studies show | 65 |
cell development | 65 |
endomyocardial biopsy | 65 |
scientific community | 65 |
occupational health | 65 |
may benefit | 65 |
polyarteritis nodosa | 65 |
genes associated | 65 |
new public | 65 |
symptom onset | 65 |
systemic circulation | 65 |
total protein | 65 |
current status | 65 |
mathematical model | 65 |
retrospectively reviewed | 65 |
oral route | 65 |
per week | 65 |
chest radiograph | 65 |
special attention | 65 |
group i | 65 |
older children | 65 |
mechanistic models | 65 |
response rate | 65 |
chest wall | 65 |
health emergencies | 65 |
general public | 65 |
cell responses | 65 |
targeted therapies | 65 |
year follow | 65 |
salmonella spp | 65 |
respiratory signs | 65 |
rare cases | 65 |
plasma levels | 65 |
febrile illness | 65 |
study population | 65 |
disease threat | 65 |
resistant staphylococcus | 64 |
vice versa | 64 |
creative commons | 64 |
clinically normal | 64 |
examples include | 64 |
neutralizing antibodies | 64 |
ischemic stroke | 64 |
also contribute | 64 |
patient died | 64 |
lateral sclerosis | 64 |
hepatic injury | 64 |
mathematical modeling | 64 |
short time | 64 |
grade i | 64 |
median survival | 64 |
health effects | 64 |
endemic regions | 64 |
asymptomatic carriers | 64 |
may remain | 64 |
animal products | 64 |
marburg virus | 64 |
various types | 64 |
every weeks | 64 |
gene mutation | 64 |
tissue samples | 64 |
new diseases | 64 |
term outcome | 64 |
lymphoid cells | 64 |
tumour necrosis | 64 |
old man | 64 |
clinical samples | 64 |
clinical syndromes | 64 |
disease research | 64 |
resistant strains | 64 |
rapid spread | 63 |
hemophagocytic lymphohistiocytosis | 63 |
included patients | 63 |
care units | 63 |
allogeneic hct | 63 |
convalescent plasma | 63 |
residual disease | 63 |
among different | 63 |
older patients | 63 |
cancer therapy | 63 |
muscular dystrophy | 63 |
function mutations | 63 |
related complications | 63 |
results obtained | 63 |
lupus nephritis | 63 |
medical record | 63 |
inflammatory cytokine | 63 |
diarrhea virus | 63 |
vein thrombosis | 63 |
progenitor cells | 63 |
factors may | 63 |
infection occurs | 63 |
risk patients | 63 |
disease include | 63 |
immune systems | 63 |
molecular techniques | 63 |
attenuated live | 63 |
relapse mortality | 63 |
reservoir hosts | 63 |
declare background | 63 |
alt activity | 63 |
mice infected | 63 |
animals will | 63 |
peritoneal dialysis | 63 |
two months | 63 |
lymphoid tissues | 63 |
vaccine candidates | 63 |
gastric ulceration | 63 |
new world | 62 |
mouse strains | 62 |
normal controls | 62 |
unknown etiology | 62 |
commonly found | 62 |
rhodococcus equi | 62 |
pediatric infectious | 62 |
bordetella bronchiseptica | 62 |
clinical study | 62 |
genetic basis | 62 |
factor viii | 62 |
vaccination strategies | 62 |
food security | 62 |
cell histiocytosis | 62 |
pid patients | 62 |
almost always | 62 |
contagious disease | 62 |
salivary gland | 62 |
three years | 62 |
sustainable development | 62 |
oxygen therapy | 62 |
neurodegenerative disease | 62 |
previously healthy | 62 |
may produce | 62 |
findings may | 62 |
control programs | 62 |
new infectious | 62 |
patients compared | 62 |
human coronavirus | 62 |
severe pneumonia | 62 |
human immune | 62 |
diffi cult | 62 |
include fever | 62 |
may predispose | 62 |
prospective cohort | 62 |
weeks later | 62 |
without clinical | 62 |
infect humans | 62 |
lessons learned | 62 |
well described | 62 |
causative agents | 62 |
en un | 62 |
gastric emptying | 62 |
comparative study | 62 |
interstitial nephritis | 62 |
humoral immune | 62 |
amyotrophic lateral | 62 |
silico modeling | 62 |
radiation exposure | 62 |
viral respiratory | 62 |
first century | 61 |
parainfluenza virus | 61 |
upper airway | 61 |
submit samples | 61 |
ulcer disease | 61 |
bl mice | 61 |
vascular endothelium | 61 |
biological weapons | 61 |
specific diseases | 61 |
commonly reported | 61 |
death rate | 61 |
heart block | 61 |
reperfusion injury | 61 |
kg iv | 61 |
weighted imaging | 61 |
negative results | 61 |
childhood cancer | 61 |
may prove | 61 |
experimentally induced | 61 |
healthy volunteers | 61 |
sars patients | 61 |
higher rates | 61 |
vascular permeability | 61 |
complex diseases | 61 |
health management | 61 |
diagnosis may | 61 |
southern china | 61 |
platelet counts | 61 |
significant role | 61 |
neonatal lupus | 61 |
neonatal period | 61 |
maternal antibody | 61 |
canine parvovirus | 61 |
study aimed | 61 |
oxygen saturation | 61 |
clinical presentations | 61 |
study demonstrated | 61 |
complete response | 61 |
disease mechanisms | 61 |
may induce | 61 |
image quality | 61 |
cell depletion | 61 |
typhoid fever | 61 |
septal defect | 61 |
colorectal carcinoma | 61 |
candida albicans | 61 |
also occurs | 61 |
within years | 60 |
cell carcinomas | 60 |
may improve | 60 |
one another | 60 |
severe ea | 60 |
first week | 60 |
alveolar walls | 60 |
examination revealed | 60 |
hepatic fibrosis | 60 |
may allow | 60 |
igg levels | 60 |
contact network | 60 |
partial response | 60 |
adult mice | 60 |
three months | 60 |
humoral immunity | 60 |
will occur | 60 |
possible role | 60 |
randomised controlled | 60 |
contaminated water | 60 |
cell infiltration | 60 |
last two | 60 |
highly effective | 60 |
tumor suppressor | 60 |
lymphatic vessels | 60 |
health conditions | 60 |
growth rate | 60 |
urea nitrogen | 60 |
contrast agents | 60 |
adult onset | 60 |
modified live | 60 |
risk group | 60 |
emergency response | 60 |
primary prevention | 60 |
laboratory diagnosis | 60 |
resistant bacteria | 60 |
organ dysfunction | 60 |
disease study | 60 |
pathogenic bacteria | 60 |
disease free | 60 |
approximately one | 60 |
risk communication | 60 |
skin biopsy | 60 |
serum concentrations | 60 |
affected foals | 60 |
organ transplantation | 60 |
effective vaccine | 60 |
many people | 60 |
frequently associated | 60 |
likely due | 60 |
initial presentation | 60 |
virus outbreak | 60 |
gene mutations | 60 |
genetic risk | 60 |
human services | 60 |
complex networks | 60 |
related genes | 60 |
angiotensin ii | 59 |
disease risks | 59 |
thrombocytopenic purpura | 59 |
research council | 59 |
sea level | 59 |
wall thickness | 59 |
obstructive lung | 59 |
multicenter study | 59 |
clinical syndrome | 59 |
disease association | 59 |
airborne transmission | 59 |
data available | 59 |
influenza infection | 59 |
therapeutic approach | 59 |
growth retardation | 59 |
live attenuated | 59 |
bacillus anthracis | 59 |
normal dogs | 59 |
clinical sign | 59 |
pulmonary infection | 59 |
lower airway | 59 |
tissue disease | 59 |
higher mortality | 59 |
viral pneumonia | 59 |
part ii | 59 |
european centre | 59 |
study included | 59 |
another example | 59 |
clinical applications | 59 |
skin disease | 59 |
creatinine ratio | 59 |
pulmonary lesions | 59 |
lavage fluid | 59 |
cell populations | 59 |
tailed deer | 59 |
old woman | 59 |
many factors | 59 |
external examination | 59 |
may prevent | 59 |
hemolytic uremic | 59 |
marginal zone | 59 |
based models | 59 |
drug use | 59 |
natural reservoir | 59 |
two distinct | 59 |
aleutian disease | 59 |
data sets | 59 |
hepatitis virus | 59 |
presumptive diagnosis | 59 |
von willebrand | 59 |
reverse transcription | 59 |
healthy cats | 59 |
type iv | 59 |
signifi cantly | 58 |
syndrome associated | 58 |
con una | 58 |
spectrum antibiotics | 58 |
control subjects | 58 |
myalgic encephalomyelitis | 58 |
epidermal growth | 58 |
bacterial culture | 58 |
negative impact | 58 |
male patients | 58 |
molecular epidemiology | 58 |
early treatment | 58 |
electronic medical | 58 |
cellular immune | 58 |
heat shock | 58 |
health department | 58 |
reference ranges | 58 |
study design | 58 |
mitochondrial dysfunction | 58 |
maintenance therapy | 58 |
highly infectious | 58 |
inflammatory syndrome | 58 |
sequence data | 58 |
gastric mucosa | 58 |
cells within | 58 |
based methods | 58 |
treatment protocols | 58 |
tissue injury | 58 |
vaccine efficacy | 58 |
cell wall | 58 |
hepatorenal syndrome | 58 |
syndrome virus | 58 |
genetic susceptibility | 58 |
obstructive sleep | 58 |
studies indicate | 58 |
recent report | 58 |
neurological signs | 58 |
final diagnosis | 58 |
severe clinical | 58 |
small airways | 58 |
management strategies | 58 |
young adult | 58 |
healthcare systems | 58 |
drug users | 58 |
linear regression | 57 |
ebola epidemic | 57 |
ejection fraction | 57 |
leading causes | 57 |
clinical care | 57 |
early recognition | 57 |
cell numbers | 57 |
pulmonary arteries | 57 |
first years | 57 |
clinical medicine | 57 |
atypical pneumonia | 57 |
bacterial overgrowth | 57 |
small numbers | 57 |
potential impact | 57 |
safety profile | 57 |
acute graft | 57 |
global trends | 57 |
benefi ts | 57 |
studies revealed | 57 |
significant changes | 57 |
stranded rna | 57 |
extremely important | 57 |
human lung | 57 |
occurs within | 57 |
lyme borreliosis | 57 |
supplementary material | 57 |
time point | 57 |
infectious virus | 57 |
international trade | 57 |
protein concentration | 57 |
genetic predisposition | 57 |
renal impairment | 57 |
iga nephropathy | 57 |
travel restrictions | 57 |
diseases will | 57 |
human primates | 57 |
coronavirus pneumonia | 57 |
blood urea | 57 |
maternal antibodies | 56 |
main cause | 56 |
induced lung | 56 |
practice guidelines | 56 |
disease among | 56 |
genetic studies | 56 |
free radicals | 56 |
early life | 56 |
cats may | 56 |
widely accepted | 56 |
current knowledge | 56 |
adhesion molecule | 56 |
like symptoms | 56 |
kinase inhibitors | 56 |
commonly affected | 56 |
small molecules | 56 |
suspected cases | 56 |
tumor growth | 56 |
inflammatory changes | 56 |
clinical conditions | 56 |
natural disasters | 56 |
widespread use | 56 |
useful tool | 56 |
activated protein | 56 |
diagnostic laboratories | 56 |
immunosuppressive drugs | 56 |
lymphocyte counts | 56 |
early disease | 56 |
care facilities | 56 |
rapidly progressive | 56 |
also shown | 56 |
dna repair | 56 |
assessed using | 56 |
increased frequency | 56 |
new drugs | 56 |
year survival | 56 |
protein synthesis | 56 |
microbial threats | 56 |
diagnostic laboratory | 56 |
infectious causes | 56 |
wild animal | 56 |
water supplies | 56 |
different species | 56 |
also include | 56 |
neurological disorders | 56 |
genome editing | 56 |
may act | 56 |
blood ammonia | 56 |
disease states | 56 |
year later | 56 |
new therapeutic | 56 |
zoonotic potential | 56 |
identify patients | 56 |
high rates | 56 |
monkeypox virus | 56 |
treatment group | 56 |
clinical setting | 56 |
nuclear factor | 56 |
mass vaccination | 56 |
curative treatment | 56 |
minimally invasive | 56 |
development goals | 56 |
platelet engraftment | 56 |
median duration | 55 |
coagulation factors | 55 |
chest radiography | 55 |
socioeconomic status | 55 |
correct diagnosis | 55 |
acute inflammation | 55 |
later stages | 55 |
diffuse large | 55 |
medical school | 55 |
metastatic disease | 55 |
el manejo | 55 |
competing interests | 55 |
bacterial species | 55 |
total body | 55 |
artificial intelligence | 55 |
common disease | 55 |
matched related | 55 |
sendai virus | 55 |
hepatic function | 55 |
geographic distribution | 55 |
toxic effects | 55 |
factors affecting | 55 |
mortality among | 55 |
diseases associated | 55 |
flow cytometric | 55 |
hand hygiene | 55 |
analysis using | 55 |
venous thrombosis | 55 |
alveolar proteinosis | 55 |
child health | 55 |
intestinal wall | 55 |
lymphocytic choriomeningitis | 55 |
borne pathogens | 55 |
human host | 55 |
complex disease | 55 |
group ii | 55 |
prevent infection | 55 |
sedimentation rate | 55 |
por el | 55 |
end stage | 55 |
controlled study | 55 |
unclear whether | 55 |
potentially fatal | 55 |
ten patients | 55 |
icu patients | 55 |
neurological symptoms | 55 |
langerhans cell | 55 |
bubonic plague | 55 |
viral pathogens | 55 |
disease state | 55 |
companion animal | 55 |
one example | 55 |
patients suffering | 55 |
induced arthritis | 55 |
inflammatory infiltrate | 55 |
sibling donor | 55 |
renal diseases | 55 |
pneumonic plague | 55 |
human respiratory | 55 |
virus may | 55 |
increasing evidence | 55 |
side effect | 55 |
congo hemorrhagic | 55 |
relapse rate | 55 |
otherwise healthy | 55 |
increased production | 55 |
functional imaging | 55 |
model parameters | 55 |
line therapy | 55 |
se debe | 54 |
changes may | 54 |
solid organ | 54 |
live vaccines | 54 |
similar clinical | 54 |
kg orally | 54 |
directly related | 54 |
often seen | 54 |
research institute | 54 |
health policies | 54 |
died due | 54 |
new coronavirus | 54 |
passive immunity | 54 |
showed significant | 54 |
virus diseases | 54 |
consensus statement | 54 |
helicobacter spp | 54 |
physical exam | 54 |
may still | 54 |
prothrombin time | 54 |
clinical status | 54 |
strongly associated | 54 |
antibody production | 54 |
human patients | 54 |
dna sequence | 54 |
iu ml | 54 |
close proximity | 54 |
central america | 54 |
therapeutic strategy | 54 |
vaccination program | 54 |
animal shelters | 54 |
people living | 54 |
parenteral nutrition | 54 |
high grade | 54 |
imaging features | 54 |
related disease | 54 |
screening test | 54 |
virus vaccines | 54 |
biopsy showed | 54 |
endothelial growth | 54 |
doberman pinschers | 54 |
disease map | 54 |
associated diseases | 54 |
copies ml | 54 |
crispr cas | 54 |
tropical countries | 54 |
ace expression | 54 |
recently published | 54 |
new virus | 54 |
gastrointestinal symptoms | 54 |
evolutionary medicine | 54 |
visceral leishmaniasis | 54 |
diarrheal disease | 54 |
eosinophilic gastroenteritis | 54 |
tick paralysis | 54 |
short stature | 54 |
lymphoid organs | 54 |
central africa | 54 |
global climate | 54 |
traumatic brain | 54 |
false positive | 54 |
rapid detection | 54 |
serum alt | 54 |
corona virus | 54 |
also increased | 54 |
histopathologic examination | 54 |
cardiovascular events | 54 |
blood smear | 53 |
defi ned | 53 |
patient received | 53 |
cutaneous manifestations | 53 |
disease cases | 53 |
serum igg | 53 |
important part | 53 |